AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16278088 — intervention group
Group type: COMPARATOR
Intervention: Valproic Acid (VPA)
Number of subjects: 239
Study 11914160 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 193
Study 11914160 — intervention group
Group type: COMPARATOR
Intervention: Combined (diclofenac plus EA)
Number of subjects: 193
Study 11914160 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 193
Study 11914160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 9891174 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7802126 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2 and 65% O2 inhalation
Number of subjects: 81
Study 7802126 — intervention group
Group type: COMPARATOR
Intervention: Placebo mixture of compressed air
Number of subjects: 81
Study 2112374 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate (n = 21)
Number of subjects: 40
Study 2112374 — intervention group
Group type: COMPARATOR
Intervention: Desipramine hydrochloride (n = 19)
Number of subjects: 40
Study 2112374 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 40
Study 2112374 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 40
Study 7395656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 63
Study 7395656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 31640797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation with the Ventilation Feedback Device (VFD) using a mask
Number of subjects: 40
Study 31640797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation with the Ventilation Feedback Device (VFD) using an endotracheal tube (ETT)
Number of subjects: 40
Study 31640797 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual ventilation (without VFD)
Number of subjects: 40
Study 28598285 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) and myo-inositol (MI)
Number of subjects: 60
Study 28598285 — intervention group
Group type: COMPARATOR
Intervention: Myo-inositol (MI) with oral hygiene instructions
Number of subjects: 60
Study 25527036 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose pre-learning
Number of subjects: 80
Study 25527036 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose post-learning
Number of subjects: 80
Study 25527036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25527036 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose at retrieval
Number of subjects: 80
Study 25527036 — intervention group
Group type: COMPARATOR
Intervention: Placebo at retrieval
Number of subjects: 80
Study 23682073 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day folic acid supplement
Number of subjects: 791
Study 23682073 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment without folic acid)
Number of subjects: 791
Study 21383272 — intervention group
Group type: EXPERIMENTAL
Intervention: Licensed cartoon characters on cereal box
Number of subjects: 80
Study 21383272 — intervention group
Group type: COMPARATOR
Intervention: No licensed cartoon characters on cereal box
Number of subjects: 80
Study 21383272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal named Healthy Bits
Number of subjects: 80
Study 21383272 — intervention group
Group type: COMPARATOR
Intervention: Cereal named Sugar Bits
Number of subjects: 80
Study 19159632 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid) 3 g
Number of subjects: 12
Study 19159632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17317022 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4) treatment after 7 weeks
Number of subjects: 6
Study 17317022 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 age-matched controls)
Number of subjects: 6
Study 15632894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin therapy with compliance-enhancing program (standardized contacts, 9 mailings, 6 telephone calls, access to a Web page and hotline) for 12 months
Number of subjects: 7598
Study 15632894 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin therapy without compliance-enhancing program
Number of subjects: 7598
Study 11504432 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide eugenol
Number of subjects: 202
Study 11504432 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 202
Study 11504432 — intervention group
Group type: COMPARATOR
Intervention: Enamel bonding resin
Number of subjects: 202
Study 11504432 — intervention group
Group type: COMPARATOR
Intervention: Adhesive bonded composites
Number of subjects: 202
Study 11504432 — intervention group
Group type: COMPARATOR
Intervention: No infection
Number of subjects: 202
Study 11504432 — intervention group
Group type: COMPARATOR
Intervention: Infection present
Number of subjects: 202
Study 9625576 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine, cytarabine, and G-CSF (FLAG)
Number of subjects: 38
Study 7876398 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sparfloxacin
Number of subjects: 12
Study 7876398 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sparfloxacin
Number of subjects: 12
Study 7876398 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg sparfloxacin
Number of subjects: 12
Study 7876398 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg sparfloxacin
Number of subjects: 12
Study 3247592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine administered at 1815 h
Number of subjects: 12
Study 3247592 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine administered at 2200 h
Number of subjects: 12
Study 31976786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 intravenously on days 3 and 10; plus veliparib 80 mg orally twice per day on days 1 to 12, cycled every 3 weeks (Arm A)
Number of subjects: 50
Study 31976786 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 intravenously on days 3 and 10 (Arm B)
Number of subjects: 50
Study 31976786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine with veliparib (Arm A)
Number of subjects: 50
Study 31976786 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine (Arm B)
Number of subjects: 50
Study 31976786 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 50
Study 30145306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Working Memory Training (CWMT)
Number of subjects: 60
Study 30145306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Working Memory Training (CWMT) with medication
Number of subjects: 60
Study 28681902 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomographic and Biomechanical Index (TBI)
Number of subjects: 94
Study 28681902 — intervention group
Group type: COMPARATOR
Intervention: Belin/Ambrósio Deviation (BAD-D)
Number of subjects: 94
Study 28681902 — intervention group
Group type: COMPARATOR
Intervention: Corvis Biomechanical Index (CBI)
Number of subjects: 94
Study 26606405 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call center follow-up
Number of subjects: 4325
Study 26606405 — intervention group
Group type: EXPERIMENTAL
Intervention: Military healthcare utilization database (M2)
Number of subjects: 4325
Study 26606405 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined follow-up strategies (web-based, telephone, M2)
Number of subjects: 4325
Study 26606405 — intervention group
Group type: COMPARATOR
Intervention: Web-based survey only
Number of subjects: 4325
Study 26606405 — intervention group
Group type: COMPARATOR
Intervention: Telephone call only
Number of subjects: 4325
Study 26606405 — intervention group
Group type: COMPARATOR
Intervention: Both web-based and telephone survey
Number of subjects: 4325
Study 23643177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine (cisplatin 60 mg/m² day 1 plus gemcitabine 1000 mg/m² days 1 and 8, repeated every 3 weeks for up to 4 cycles)
Number of subjects: 57
Study 23643177 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (1200 mg/m² days 1 and 8, repeated every 3 weeks for up to 4 cycles)
Number of subjects: 57
Study 23643177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine
Number of subjects: 57
Study 23643177 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 57
Study 21547834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 14
Study 18294251 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan (12.5 mg) administered when pain intensity was mild (within 1 h of headache onset)
Number of subjects: 491
Study 18294251 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan (12.5 mg) administered when pain intensity was moderate/severe
Number of subjects: 491
Study 18294251 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered when pain intensity was mild
Number of subjects: 491
Study 18294251 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered when pain intensity was moderate/severe
Number of subjects: 491
Study 18294251 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan (12.5 mg) for sustained pain free
Number of subjects: 491
Study 17418720 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic composite resin modified by benzalkonium chloride (BAC)
Number of subjects: 80
Study 17418720 — intervention group
Group type: COMPARATOR
Intervention: Control group (unmodified orthodontic composite resin)
Number of subjects: 80
Study 17418720 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic composite resin modified by BAC
Number of subjects: 80
Study 14744291 — intervention group
Group type: EXPERIMENTAL
Intervention: New technologies in neuroendovascular intervention
Number of subjects: 0
Study 11514117 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava extract with hormone replacement therapy
Number of subjects: 0
Study 11514117 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy (with and without progestogens)
Number of subjects: 0
Study 11514117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9022538 — intervention group
Group type: EXPERIMENTAL
Intervention: OKG bolus (10 g; n = 13)
Number of subjects: 42
Study 9022538 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous gastric infusion of OKG (10, 20, or 30 g/d over 21 h; n = 13)
Number of subjects: 42
Study 9022538 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous control (n = 16)
Number of subjects: 42
Study 7528032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation (surgical or radiotherapeutic ablation, LH-RH agonists)
Number of subjects: 1800
Study 7528032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation (adjuvant therapy)
Number of subjects: 1800
Study 7528032 — intervention group
Group type: COMPARATOR
Intervention: Ovarian ablation (compared to adjuvant chemotherapy)
Number of subjects: 1800
Study 3236298 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 47
Study 3236298 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 47
Study 3236298 — intervention group
Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 47
Study 3236298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31756117 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-μg ethinylestradiol/3-mg drospirenone (EE/DRSP)
Number of subjects: 102
Study 31756117 — intervention group
Group type: COMPARATOR
Intervention: 30-μg ethinylestradiol/2-mg chlormadinone acetate (EE/CMA)
Number of subjects: 102
Study 30114195 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic (TVT) sling procedure
Number of subjects: 554
Study 30114195 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator (TVT-O) sling procedure
Number of subjects: 554
Study 30114195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 554
Study 26076737 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit™ exercise therapy
Number of subjects: 90
Study 26076737 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 90
Study 26076737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 25005937 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 17
Study 25005937 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 17
Study 25005937 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 17
Study 23046785 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused treatment for adolescents (FFT-A)
Number of subjects: 58
Study 20429697 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined potassium and sodium channel blocking agent for conversion of atrial fibrillation
Number of subjects: 145
Study 20429697 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of combined potassium and sodium channel blocking agent
Number of subjects: 145
Study 20429697 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without morphological T wave changes)
Number of subjects: 145
Study 19281063 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuits (100 mg IF aglycones/two servings)
Number of subjects: 42
Study 19281063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal bars (100 mg IF aglycones/two servings)
Number of subjects: 42
Study 19281063 — intervention group
Group type: COMPARATOR
Intervention: Comparison of biscuits and cereal bars
Number of subjects: 42
Study 16032424 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume Support Ventilation (VSV)
Number of subjects: 10
Study 16032424 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 10
Study 11507934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.243% sodium fluoride dentifrice containing 7% sodium hexametaphosphate
Number of subjects: 0
Study 11507934 — intervention group
Group type: COMPARATOR
Intervention: 0.243% sodium fluoride control dentifrice
Number of subjects: 0
Study 10190392 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 400 microg + vitamin B12 500 microg + vitamin B6 12.5 mg
Number of subjects: 95
Study 10190392 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 1 mg + vitamin B12 500 microg + vitamin B6 12.5 mg
Number of subjects: 95
Study 10190392 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg + vitamin B12 500 microg + vitamin B6 12.5 mg
Number of subjects: 95
Study 10190392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 7751732 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + CPFX
Number of subjects: 53
Study 7751732 — intervention group
Group type: COMPARATOR
Intervention: ST
Number of subjects: 53
Study 2310652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (200 mg or 400 mg)
Number of subjects: 15
Study 2310652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 338663 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative approach
Number of subjects: 1030
Study 338663 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic approach
Number of subjects: 1030
Study 31642084 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT) applied over 4 weeks, consisting of eight modules.
Number of subjects: 0
Study 31642084 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study 30858274 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Training (8-hour course)
Number of subjects: 41
Study 30858274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MI training)
Number of subjects: 41
Study 28199305 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (3 doses of 5.12 × 10^4 PfSPZ at 28-day intervals)
Number of subjects: 35
Study 28199305 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (3.2 × 10^3 PfSPZ)
Number of subjects: 35
Study 28199305 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (1.28 × 10^4 PfSPZ)
Number of subjects: 35
Study 28199305 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (5.12 × 10^4 PfSPZ at five-day intervals)
Number of subjects: 35
Study 25521872 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy (extra incentives, reinforcement, feedback, and skill-building guidance)
Number of subjects: 435
Study 25521872 — intervention group
Group type: COMPARATOR
Intervention: Basic dissemination strategy
Number of subjects: 435
Study 25521872 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy
Number of subjects: 435
Study 23498965 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200mg) intravenously once a day for two days
Number of subjects: 38
Study 23498965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) intravenously once a day for two days
Number of subjects: 38
Study 21220657 — intervention group
Group type: EXPERIMENTAL
Intervention: HITIDES intervention (collaborative care with a registered nurse, pharmacist, and psychiatrist for up to 12 months)
Number of subjects: 249
Study 21220657 — intervention group
Group type: EXPERIMENTAL
Intervention: HITIDES intervention
Number of subjects: 249
Study 21220657 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 249
Study 18952242 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 8
Study 18952242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17531571 — intervention group
Group type: EXPERIMENTAL
Intervention: Binodenoson 1.5 microg/kg bolus
Number of subjects: 133
Study 17531571 — intervention group
Group type: EXPERIMENTAL
Intervention: Binodenoson 0.3, 0.5, or 1 microg/kg/min infusion
Number of subjects: 133
Study 17531571 — intervention group
Group type: EXPERIMENTAL
Intervention: Binodenoson 1.5 or 3 microg/kg bolus
Number of subjects: 133
Study 17531571 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of binodenoson
Number of subjects: 133
Study 15364220 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (0.5% Timoptic‐XE)
Number of subjects: 18
Study 15364220 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005% Xalatan)
Number of subjects: 18
Study 15364220 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 18
Study 11336101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin extended-release 80 mg
Number of subjects: 40
Study 11336101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin extended-release 160 mg
Number of subjects: 40
Study 11336101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin extended-release 320 mg
Number of subjects: 40
Study 11336101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin extended-release 640 mg
Number of subjects: 40
Study 11336101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9601592 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine gel (2.5 mg/ml)
Number of subjects: 12
Study 9601592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen gel (1.6 mg/ml)
Number of subjects: 12
Study 7978179 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 30
Study 7978179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study 2492832 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin (IgG) therapy
Number of subjects: 12
Study 2492832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1273209 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg delta9-tetrahydrocannabinol (THC)
Number of subjects: 20
Study 1273209 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg delta9-tetrahydrocannabinol (THC)
Number of subjects: 20
Study 1273209 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg delta9-tetrahydrocannabinol (THC)
Number of subjects: 20
Study 1273209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1273209 — intervention group
Group type: EXPERIMENTAL
Intervention: delta9-tetrahydrocannabinol (THC)
Number of subjects: 20
Study 30359204 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, integrated palliative care (PC)
Number of subjects: 19
Study 30359204 — intervention group
Group type: COMPARATOR
Intervention: Usual oncology care
Number of subjects: 19
Study 28005621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ram Relaxation Technique (RRT)
Number of subjects: 20
Study 26278784 — intervention group
Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention used once per month for 6 months
Number of subjects: 179
Study 26278784 — intervention group
Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention
Number of subjects: 179
Study 26278784 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 179
Study 24041518 — intervention group
Group type: EXPERIMENTAL
Intervention: New method of microskin autografting with a Vaseline-based moisture dressing
Number of subjects: 52
Study 24041518 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of microskin autografting
Number of subjects: 52
Study 24041518 — intervention group
Group type: EXPERIMENTAL
Intervention: New method of microskin autografting
Number of subjects: 52
Study 21849285 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of abacavir-lamivudine-zidovudine concurrent with tuberculosis therapy
Number of subjects: 214
Study 21849285 — intervention group
Group type: COMPARATOR
Intervention: Delayed antiretroviral therapy
Number of subjects: 214
Study 19437617 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenylephrine 10% with intracameral lidocaine 1%
Number of subjects: 20
Study 19437617 — intervention group
Group type: COMPARATOR
Intervention: Topical cyclopentolate 1% and phenylephrine 10% with intracameral lidocaine 1%
Number of subjects: 20
Study 17666348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangshenqing (TSQ) combined with basic treatment
Number of subjects: 120